Arrowhead Pharmaceuticals, Inc. (ARWR) Stock
Arrowhead Pharmaceuticals, Inc. (ARWR) is a Healthcare stock trading at $81.72 (as of 2026-06-18), with a market capitalization of $10.22B and a trailing P/E of -35.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Insufficient source information was provided from Signals.AI’s SEC 10‑K Item 1 Business section to produce a fact-based description under the stated rules.
Valuation — source: SEC EDGAR (first-party) Price $81.72 Market Cap $10.22B P/E Ratio -35.9 EV / EBITDA -56.6 Price / Book 19.06 Price / Sales 18.35 DCF Value (model) $18.75 DCF Upside vs Price -77.1%
Profitability & Growth — source: SEC EDGAR Revenue (TTM) $829.45M Net Margin -0.2% Return on Equity -50.2% Current Ratio 6.23 Revenue Growth (YoY) 10461.3% EPS Growth (YoY) -115.8% FCF Growth (YoY) -107.4%
Financial Health — source: SEC EDGAR Altman Z-Score 7.39 (safe)
Valuation vs Sector & Industry Stock P/E -35.9 Sector P/E (Healthcare) 21.0 Industry P/E (Pharmaceutical Products) 17.3 vs Sector -271.1% vs Industry -307.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures Top Institutional Holder BlackRock, Inc. ($1.14B) Institutional Holders Tracked 10 Congressional Trades (recent) 1
Company Sector Healthcare Industry Pharmaceutical Products CEO Christopher R. Anzalone Employees 609 Country US IPO Date 1993-12-16
Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled) ARWR earnings history · ARWR institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener Data as of 2026-06-18.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.